SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in ...

Please provide your email address to receive an email when new articles are posted on . “Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk,” Sabashini ...

EAST HANOVER, N.J., June 5 /PRNewswire/ -- The US Food and Drug Administration (FDA) has broadened the US indication for once-yearly Reclast(R) (zoledronic acid) Injection to include the prevention of ...

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard ...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis Study of over 7,700 women published today shows reduction of 70 percent in spine fractures and 41 ...

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results ...

EAST HANOVER, N.J., Dec. 11 /PRNewswire/ -- New data released today demonstrate that the addition of Zometa® (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces ...

March 30, 2005 ( updated April 5, 2005) — The U.S. Food and Drug Administration (FDA) approved in January revisions to safety labeling to advise healthcare professionals of the following changes: use ...